These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
400 related items for PubMed ID: 15637527
21. Effect of cimetidine and probenecid on pilsicainide renal clearance in humans. Shiga T, Hashiguchi M, Urae A, Kasanuki H, Rikihisa T. Clin Pharmacol Ther; 2000 Mar; 67(3):222-8. PubMed ID: 10741624 [Abstract] [Full Text] [Related]
22. Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine. Banfield C, Gupta S, Marino M, Lim J, Affrime M. Clin Pharmacokinet; 2002 Mar; 41(4):311-8. PubMed ID: 11978146 [Abstract] [Full Text] [Related]
23. Effects of multiple-dose rifampicin 450 mg on the pharmacokinetics of fexofenadine enantiomers in Japanese volunteers. Akamine Y, Miura M, Yasui-Furukori N, Ieiri I, Uno T. J Clin Pharm Ther; 2015 Feb; 40(1):98-103. PubMed ID: 25263393 [Abstract] [Full Text] [Related]
24. Effects of single and multiple doses of itraconazole on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. Shimizu M, Uno T, Sugawara K, Tateishi T. Br J Clin Pharmacol; 2006 Sep; 62(3):372-6. PubMed ID: 16796706 [Abstract] [Full Text] [Related]
25. Pharmacokinetics of fexofenadine following LPS administration to rats. Jaisue S, Gerber JP, Davey AK. Xenobiotica; 2010 Nov; 40(11):743-50. PubMed ID: 20863200 [Abstract] [Full Text] [Related]
26. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Dresser GK, Bailey DG, Leake BF, Schwarz UI, Dawson PA, Freeman DJ, Kim RB. Clin Pharmacol Ther; 2002 Jan; 71(1):11-20. PubMed ID: 11823753 [Abstract] [Full Text] [Related]
31. Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability. Lappin G, Shishikura Y, Jochemsen R, Weaver RJ, Gesson C, Houston B, Oosterhuis B, Bjerrum OJ, Rowland M, Garner C. Eur J Pharm Sci; 2010 May 12; 40(2):125-31. PubMed ID: 20307657 [Abstract] [Full Text] [Related]
32. Enantioselective disposition of fexofenadine with the P-glycoprotein inhibitor verapamil. Sakugawa T, Miura M, Hokama N, Suzuki T, Tateishi T, Uno T. Br J Clin Pharmacol; 2009 May 12; 67(5):535-40. PubMed ID: 19552748 [Abstract] [Full Text] [Related]
34. Loratadine and terfenadine interaction with nefazodone: Both antihistamines are associated with QTc prolongation. Abernethy DR, Barbey JT, Franc J, Brown KS, Feirrera I, Ford N, Salazar DE. Clin Pharmacol Ther; 2001 Mar 12; 69(3):96-103. PubMed ID: 11240972 [Abstract] [Full Text] [Related]
35. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB. Drug Metab Dispos; 1999 Aug 12; 27(8):866-71. PubMed ID: 10421612 [Abstract] [Full Text] [Related]
36. Renal interaction between itraconazole and cimetidine. Karyekar CS, Eddington ND, Briglia A, Gubbins PO, Dowling TC. J Clin Pharmacol; 2004 Aug 12; 44(8):919-27. PubMed ID: 15286096 [Abstract] [Full Text] [Related]
37. Organic anion and cation transporters are possibly involved in renal excretion of entecavir in rats. Yanxiao C, Ruijuan X, Jin Y, Lei C, Qian W, Xuefen Y, Hong T, Xueying Z, Davey AK, Jiping W. Life Sci; 2011 Jul 04; 89(1-2):1-6. PubMed ID: 21466809 [Abstract] [Full Text] [Related]
38. Effect of probenecid on the distribution and elimination of ciprofloxacin in humans. Jaehde U, Sörgel F, Reiter A, Sigl G, Naber KG, Schunack W. Clin Pharmacol Ther; 1995 Nov 04; 58(5):532-41. PubMed ID: 7586947 [Abstract] [Full Text] [Related]
39. Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using alfentanil and fexofenadine in combination. Kharasch ED, Walker A, Hoffer C, Sheffels P. J Clin Pharmacol; 2005 Jan 04; 45(1):79-88. PubMed ID: 15601808 [Abstract] [Full Text] [Related]
40. Capsaicin pretreatment enhanced the bioavailability of fexofenadine in rats by P-glycoprotein modulation: in vitro, in situ and in vivo evaluation. Bedada SK, Appani R, Boga PK. Drug Dev Ind Pharm; 2017 Jun 04; 43(6):932-938. PubMed ID: 28102715 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]